Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2019 Jan;17(1):32-34 Authors: Tam CS PMID: 30843894 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30843894?dopt=Abstract

Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research